Cyclarity Therapeutics

WATCH The Future of Longevity AT: https://lnkd.in/gdsQiRa4 Many thanks and #Gratitude to Omri Amirav-Drory and Eric Ward at NFX for creating this documentary featuring scientists making a difference in the field of #longevity. We are honored they chose to include Cyclarity Therapeutics ' CEO, Scientific Affairs, Matthew "Oki" O'Connor, Head of, Head of Scientific Computing, Amelia Anderson and Vice President of Biology, Daniel Clemens. Love the animations!! Based at the Buck Institute for Research on Aging in Novato, #California, US, we are working to reverse atherosclerosis. Our mission to provide a drug (UDP-003) that can genuinely modify the course of primary coronary heart disease, peripheral artery disease, and carotid stenosis. The drug is clinic-ready (in vials and labeled, and the safety package is being finalized). We expect phase 1 to be performed in Australia under the direction of the Victoria Heart Institute in 2024, with a multi-country, multi-site phase 2 in ’25 through ‘27. The company is currently raising a Series A-1 to fund the phase 1 trial. #JPM #JPM24 #JPM2024 #Healthspan #LifescienceVC #VentureCapital #investments #lifesciences #cyclarity #ReverseAtherosclerosis #CuringHeartDisease #endheartdisease #atherosclerosis #CuringAtherosclerosis #DiseaseReversal #HeartHealth #CardiovascularDisease #cyclodextrin #cholesterol #ScienceNeverSleeps #LiveBetterLonger #ResearchNeverSleeps #ForeverHealthy #Kizoo #Australia #US #EU #SanFrancisco #longevitylifestyle #longevitymedicine

Excited to announce that recruitment for our Ph1 clinical trial is now open! We've been fielding many many inquiries about this so we're very happy to be able to share it now! Currently healthy volunteers only - patients to start later in the year. https://lnkd.in/gqjNrb9E

Very nice write up about our lead drug and technology by Tamas Sohajda at Carbohyde! https://lnkd.in/gU4sYaYs

This is huge! https://lnkd.in/gUfe6DYJ

Great story on philanthropist / investor and Cyclarity supporter James Fickel: https://lnkd.in/gesMcCqC

New interview with our Co-CEO Matthew "Oki" O'Connor on the LongeCity podcast! https://lnkd.in/gwztMVCF

Exciting News! ?? We at Cyclarity are thrilled to announce that we have officially submitted our trial application to the Human Research Ethics Committees (HREC) in Australia for our First in Human clinical trial! This milestone marks our transition to a clinical-stage company, and we couldn’t be more proud of our hardworking team in California. ?? Our upcoming clinical trial will be conducted at CMAX in Adelaide, partnered with Monash University under the esteemed guidance of Dr. Stephen Nicholls, a world-renowned cardiologist and leader at the Victorian Heart Institute (VHI). Stay tuned for more updates as we embark on this exciting journey towards groundbreaking advancements in healthcare! #Cyclarity #ClinicalTrial #HREC #Milestone #HealthcareInnovation #Cardiology

Dr. O'Connor speaking at Longevity Summit Dublin in June. Take a look! https://lnkd.in/dT-nqzcv

Dr. Daniel M. Clemens, our V.P. of Biology, will be presenting at the 2024 European Atherosclerosis Society Congress in Lyon on Tuesday, May 28. Daniel will be presenting new and exciting data about the efficacy and clinical readiness of UDP-003, our intended first-in-class therapeutic for the reversal of atherosclerosis. Come by the Science at a Glance presentation, or contact Daniel directly to setup a meeting. https://lnkd.in/d9_HdhvE To contact Daniel: https://lnkd.in/gyMZKH7V Visit https://cyclaritytx.com to learn more about our revolutionary approach to curing heart disease. #cyclarity #cureheartdisease #EASCongress2024 #EAS2024 #atherosclerosis #CVD #cholesterol

CONGRATULATIONS to our Head of Scientific Computing & Co-Founder, Dr. Amelia Anderson, for achieving a PhD summa cum laude for her novel work in computational molecular modeling, which is central to Cyclarity’s approach to curing heart disease! #cyclarity #cureheartdisease #cyclodextrins